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Introduction 
Terminal catastrophic haemorrhage, includ-
ing intracranial haemorrhages, in the pallia-
tive care setting is a rare clinical reality that 
has profound effects encompassing imminent 
and rapid death of the patient and distressing 
and dramatic implications for the health care 
staff and the patient’s family. The manage-
ment of this clinical palliative emergency is 
based largely on anecdotal and experiential 
guidelines, with no high-grade evidence, ra-
ther robust contention and controversy. 
By definition, a terminal catastrophic haemor-
rhage is a major arterial bleed whereby death 
is rapid due to the significant internal or ex-
ternal loss of blood volume (Harris & Noble 
2009). The clinical context for the purpose of 
this enquiry into practice is in the advanced 
cancer demographic in “whom invasive or 
interventional procedures and cardiopulmo-
nary resuscitative measures are no longer 
appropriate” (Harris & Noble 2009, p 914). 
The goals of care are for supportive palliative 
care and comfort (Pereira & Phan, 2004). 
With respect to the assessment task it is evi-
dent that there is a paucity of literature direct-
ly related to terminal catastrophic cerebral or  
intracranial bleeds. In much of the literature, 
it is often referenced in relation to tumours of  
the head and neck within the haematological 
cancer literature and management guidelines 
identified under various generic terminologies 
including palliative emergencies, bleeding, 
acute or sudden severe haemorrhage. 
Patients with large intracranial haemorrhages 
may be identifiable as presenting with a rapid 
onset of neurological symptoms, decreased 
consciousness related to increased intracra-
nial pressure and a low Glasgow Coma 
Scale (GCS) rating (Quinones Hinojosa, Gu-
lati, Singh & Lawton, 2003). Koji, Manabu, 
Osamu, Takahiro, Toshikazu, Junya & 
Naoyuki (2014) also identify the rare but evi-
dent cases of radiation induced intracranial 
aneurysms in the head and neck tumour pa-
tient population. As these aneurysms origi-
nate from arterial walls they can rupture, dis-
sect the artery and produce catastrophic ex-
travasation of arterial blood leading to subse-
quent hypovolaemia and possibly death (Koji 
et al., 2014). Definitive diagnosis requires 
radiological imaging, however in end-stage 
palliative management this would be unnec-
essary. 
Harris & Noble (2009) submit that most of the 
figures quoted in the literature related to pa-
tients with head and neck cancers but there 
was no definitive data available for death by 
haemorrhage or type of cancer. More acutely 
Chen, Tai, Tsay, Chen, & Tien (2009) identi-
fied intracranial haemorrhage as the second 
leading cause of death in the acute myeloid 
leukaemia patient population and 14% of 
patients died of fatal haemorrhage in the in-
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duction phase of treatment. Quinones-
Hinojosa et al (2003) identified acute leukae-
mia with thrombocytopaenia and the haemo-
philia patient population at risk of death 
caused by massive intracranial haemorrhage - 
fatal in 50% of cases. From the literature and 
available guidelines it seems that irrespective 
of the location of the fatal haemorrhage, the 
planning, care, support and management ap-
pears to be largely the same. 
Palliative care is the primary specialty at this 
Victorian small sub-acute facility comprising of 
an inpatient ward and community nursing ser-
vice. Surprisingly, there are no written poli-
cies, procedures, clinical pathways or hospital 
guidelines available for the management of 
catastrophic haemorrharge. In separate dis-
cussions with the manager of the Community 
Palliative Care Service, the Nurse Unit Man-
ager of the in-patient ward and the Clinical 
Director of Palliative Care, the key areas that 
management identified were: risk identifica-
tion, supportive practices such as having dark 
towels to camouflage blood loss, the im-
portance of staying with the patient, anticipa-
tory medication orders for midazolam and 
morphine either intramuscularly or intrave-
nously, staff support and advanced care plan-
ning. However, all these practices and 
knowledge were experientially based and his-
torically rooted in current practice.  
This did however, support much of the litera-
ture on the palliative management of terminal 
haemorrhage and the level of evidence availa-
ble to guide practice. Harris & Noble (2009) 
highlight in their systematic literature review 
that none of the literature on the palliative 
management of terminal haemorrhage was 
above a Level 5 on the Oxford Centre for Evi-
dence Based Medicine Level of Evidence 
(2009). Level 5 evidence is rated as “based 
on expert opinion without explicit critical ap-
praisal or based on physiology, bench re-
search or first principles” (Harris & Noble 
2009, p 915). This similarly reflects the level 
of evidence rated as Level 5 in the more re-
cent Joanna Briggs Institute (JBI) Best Prac-
tice Recommendations with particular refer-
ence to using crisis medications in the pallia-
tive care terminal haemorrhage scenarios for 
both inpatient and community care scenarios 
(JBI, 2014). McGrath & Leahy (2009) also 
submit that there is scant research on the top-
ic of catastrophic bleeds during end of life 
care, identifying personal preference and an-
ecdotal reports guide health professionals. 
Whilst the focus of their research and guide-
lines is end of life haematology, the broader 
care and supportive management overlap in 
both identified practices as well as the contro-
versies. 
The incidence of catastrophic bleeding is rare 
in the advanced cancer population and is cit-
ed by Harris & Noble (2009) to be between 3-
12 % or 6-10% (McGrath & Leahy, 2009). 
Whilst rare, catastrophic bleeds are a signifi-
cant palliative care emergency associated 
with certain, often imminent death.  Within the 
literature there are 3 - 4 key areas, including 
identifying at risk patients, employing key sup-
portive measures, the use of sedative medica-
tion and ethical issues faced in the manage-
ment of terminal haemorrhage (Harris & No-
ble, 2009). 
Chen et al. (2009) identify in their retrospec-
tive study prolonged prothrombin time, prior 
brainstem haemorrhage, subarachnoid haem-
orrhage and epidural haemorrhage as prog-
nostic factors in intracranial haemorrhage in 
acute myeloid leukaemia patients, particularly 
the acute promyelocytic leukaemia sub group 
of patients. Quinones Hinojosa et al., (2003) 
cite Graus, Rogers & Posner’s (1985) work 
that identifies the acute promyelocitic leukae-
mia patient population as high risk, given 
more than 60% die of intracranial haemor-
rhage. Whilst early detection of coagulopathy 
and swift correction can reduce haemorrhagic 
complications (Chen et al., 2009), Pereira & 
Phan (2004) suggest the benefit versus bur-
den of anticoagulant therapy and monitoring 
must be considered, particularly in advanced 
disease. 
In the head and neck cancer population the 
main risk factors are surgery, radiotherapy, 
postoperative healing issues, visible arterial 
pulsation, the presence of a pharyngocutane-
ous fistula, fungating tumours with artery inva-
sion and other generalised factors such as 
being over the age of  50years, 10-15% body 
weight loss, malnourishment, diabetes, immu-
nodeficiency, generalised atherosclerosis, a 
smaller precursor bleed and direct radiological 
observation of a tumour infiltrating an arterial 
wall (Harris & Noble, 2009). McGrath & Leahy 
(2009) report the possibility of identifying pa-
tients at risk of a catastrophic bleed as contro-
versial but more relevant to the haematology 
patient group, identifying acute leukaemia, 
lymphoma and myeloma patients citing throm-
bocytopenia and disseminated intravascular 
coagulation as high risk symptoms. 
Paradoxically, the distinct unpredictability of 
terminal haemorrhage is a clinical reality de-
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scribed in the Harris, Finlay, Flowers, & Noble 
(2011) study when unexpected patients haem-
orrhaged. Therefore, awareness by all nursing 
staff of the potential and a clinical care path-
way seems crucial to streamline care and 
management, particularly in relation to sup-
portive measures and to support and educate 
new, less experienced staff or students within 
the organisation. 
Much of the emphasis is placed on planning 
and implementation of supportive practice 
should terminal haemorrhage occur. Again the 
literature is limited to Level 5 evidence, based 
on a few case reports and expert opinion 
(Harris & Noble, 2009; Joanna Briggs Insti-
tute, 2014). In the literature review by Harris & 
Noble (2009) and subsequently Harris et al. 
(2011) qualitative research, merit was identi-
fied in the timely implementation of supportive 
measures. They implore the importance of 
staying with the patient, providing psychologi-
cal support to patients and their family, apply-
ing pressure if bleeding is external, using dark 
coloured or green towels to camouflage blood, 
positioning patients in a lateral position, apply-
ing oxygen and importantly debriefing and 
peer support for staff. Harris et al., (2011) 
identify through staff interviews that staying 
with the patient overrode the importance of 
getting crisis medication. They also identified 
that this is not what the guidelines have previ-
ously focused on as priority.  
These measures are reflected in the Thera-
peutic Guidelines in Palliative Care (Palliative 
Care Expert Group, 2010) and are further sup-
ported by the Yorkshire Palliative Guidelines 
(Yorkshire Palliative Medicine Clinical Guide-
lines Group, 2008) and the Scottish Palliative 
Care Guidelines on bleeding (NHS Scotland, 
2014), which propose the assurance that 
someone is with the patient at all times and 
suggest that patient support and non-drug 
management might be more important than 
any crisis medication. The Care Management 
Guidelines for Emergencies in Palliative Care 
Tasmania denote in bold, the imperative of not 
leaving a patient alone if they are having a 
severe acute haemorrhage (Department of 
Health & Human Services, 2009). Nauck & Alt
- Epping (2008) identify that one of the most 
important obligations in palliative care is being 
with the patient at this time. 
After such an event, it is widely acknowledged 
that supportive debriefing and counseling of 
staff and family is valid. Yet Harris & Noble 
(2009) identify that the management of chil-
dren who witness such an event is poorly rec-
ognised. The Yorkshire Palliative Medical 
Clinical Guidelines Group (2008) and Scottish 
Palliative Care Guidelines (2014) support 
whole team debriefing and ongoing bereave-
ment support to families and staff members as 
a necessary component of care.  
Whilst high profile in the literature and theoret-
ically sound, medication administration at this 
time is also based on limited evidence and 
has never been formally assessed (Harris et 
al., 2011). There is no clinical evidence availa-
ble to inform best route of sedative agent in 
the management of terminal haemorrhage 
(Harris & Noble, 2009). While the aim in medi-
cation administration during a terminal cata-
strophic haemorrhage is generic in assuaging 
distress and providing comfort, much conten-
tion arises across the literature in relation to 
the type of medication to use - benzodiaze-
pine versus opioids or both, the route - subcu-
taneous (S/C), intramuscular (IM), intravenous 
(IV) or rectal (PR), the dosage or indeed 
whether to use any medication at this time. 
Harris et al., (2011) conclude in their qualita-
tive study that the use of crisis medication in 
the management of terminal haemorrhage 
due to incurable cancer rarely benefits the 
patient and can detract from the supportive 
nursing care. In fact there was “complete con-
cordance” (Harris et al. 2011, p693) between 
medical and nursing staff on this point. This 
practice is supported by the JBI Best Practice 
recommendations for the use of crisis medica-
tions with palliative care patients experiencing 
terminal haemorrhage in both the hospital and 
community setting and states “providing sup-
port to the patient is the priority” (JBI 2014, 
p2), and unless prefilled syringes are instantly 
available little benefit in their use is suggested 
in the community setting. The JBI (2014) en-
courages the administration of crisis medica-
tions IV if access is available in the inpatient 
setting.  
Although the notion of prefilled syringes is 
discussed variably in the literature, it is a 
questionable practice forbidden in some or-
ganisations for sound ethical and legal rea-
sons. Whilst supportive measures are front-
line, medication administration is thought to 
benefit if the dying process is not as rapid as 
anticipated. In the absence of PICC/IV lines, 
IM administration of midazolam 10mg is pre-
ferred and repeated at 10 minutely intervals if 
indicated.  
The Yorkshire Palliative Care Guidelines 
(2008) for the management of bleeding for 
Australasian Journal of Neuroscience Volume 25 ● Number 2 ● October 2015 
 23 
palliative care patients with cancer, do inform 
and advise that if it is felt to be appropriate to 
have medication ordered, it should be rapid 
and readily available for IM or IV administra-
tion, as the S/C route is likely to be ineffectual 
due to peripheral shutdown and its’ unpredict-
able absorption and metabolism. Considera-
tion of whether the patient is opiate-naive or 
not, should be raised. Comprehensively, the 
guidelines do suggest other options such as 
diazepam PR, midazolam bucally and loraze-
pam sublingually if nursing staff were not pre-
sent - such as at home. 
The Tasmanian Care Management Guide-
lines in Emergencies in Palliative Care advo-
cate as wise, the practice of having a crisis 
order where the identified risk of severe 
bleeding and death is “inevitable”, purporting 
the merit of rapid sedation to avoid the anxie-
ty and distress the symptoms of shock pro-
duce (Department of Health & Human Ser-
vices, 2009). These guidelines are more fo-
cused around the intervention of medication 
administration at the time of haemorrhage 
and promote having the medications drawn 
up ready for use as well as some expectation 
that the family may need to administer them. 
Nowhere in these guidelines are debriefing or 
bereavement support outlined, rather the fo-
cus is on the merit of explanation to the fami-
ly of the use of medications. 
McGrath & Leahy (2009) nominate agree-
ment by the health professionals on the issue 
of administering sedation and pain relief to 
patients having a catastrophic bleed as an 
important supportive strategy. Pereira & Phan 
(2008) cite other less recent publications in 
support of having rapid sedative medications 
available and families instructed on S/C ad-
ministration. Whilst the Therapeutic Guide-
lines: Palliative Care (Palliative Care Expert 
Group, 2010), support that the unlikely effect 
of medications being administered in time to 
relieve any distress and emphasise the prac-
tice of staying with the patient, they do how-
ever propose that medications being in the 
home with instructions on how to administer 
may relieve anxiety. The local Community 
Palliative Care Service does not allow pre-
filled syringes. However there may be antici-
patory medications and orders in the home of 
patients identified at risk. 
Pereira & Phan (2004) and the JBI (2014) 
advocate for family members and health care 
providers to be sensitively informed of the 
risk and management plan of the potential for 
a terminal haemorrhage, as these events are 
always distressing. Individual consideration, 
respecting the different capacities of individu-
als and families is felt to be the better prem-
ise and the consensus identified by McGrath 
& Leahy (2009). The Yorkshire Guidelines on 
the management of bleeding for palliative 
care patients with cancer (Yorkshire Palliative 
Medicine Clinical Guidelines Group 2008), 
support that the assessment of each particu-
lar individual and family must be weighted, 
citing good practice offers the opportunity for 
patients and families to raise concerns relat-
ed to management or mode of death and es-
pecially the consideration of the presence of 
children in the home. Nauck & Alt-Epping 
(2008) propose that to a greater extent in re-
lation to impending haemorrhage than any 
other palliative care emergencies, good com-
munication, explanations and the establish-
ment of a rapport in advance with the patient 
and family is warranted.  
McGrath & Leahy (2009) identify the im-
portance of advanced care directives or a 
statement of choices, so that the appropriate 
course of management is adhered to should 
a catastrophic bleed occur, as well as prepa-
ration of the carers in the home situation. The 
Yorkshire Palliative Medicine Guidelines 
(Yorkshire Palliative Medicine Clinical Guide-
lines Group, 2008) advocate that discussions 
and decisions regarding bleeding manage-
ment should be made early, documented and 
shared with all service providers including out 
of hours services. They advocate that ad-
vanced care directives for those identified as 
high risk for major bleeding must be individu-
alised, reviewed and clearly documented. 
The Therapeutic Guidelines in Palliative Care 
(Palliative Care Expert Group, 2010) empha-
sise that if a haemorrhage is anticipated, then 
planning must include preparation of the car-
ers of the potential and how to provide com-
fort, which is felt to be paramount. The Tas-
manian Care Management Guidelines 
(Department of Health & Human Services, 
2009) identify the importance of planning, 
anticipating and having a strategy that is 
communicated early with balancing infor-
mation to the patient and carer in a way so as 
not to provoke anxiety waiting for the inevita-
ble which may never eventuate. This reflects 
some ethical issues raised in the literature 
related to informing the patient of the risk of 
terminal haemorrhage, timing and method of 
discussing patient preferences versus their 
right to know, the merit of outlining an event 
that may never occur, but potentially increas-
ing anxiety at a time of heightened angst 
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(Harris & Noble, 2009; McGrath & Leahy, 
2009). 
With increased clinical awareness and man-
agement of this phenomenon, as well as the 
identified lack of policies or procedures related 
to the management of catastrophic bleeds, it 
is believed that the development of a clinical 
pathway and supporting hospital policy is war-
ranted. Whilst the local practice is sound with-
in the current national and international guide-
lines, formal documentation rather than the 
reliance on historical practice regimes would 
be a positive educational tool for new staff and 
students.  
Conclusion 
There is clearly a scarcity in the literature re-
garding the management of catastrophic hem-
orrhages in the palliative care populous. Sev-
eral international guidelines exist to help guide 
practice. However there is no consensus re-
garding the pharmacological interventions and 
management strategies for these events. As 
this event is an inevitably dramatic and devas-
tating for the patient, their family and the 
health professionals involved, potentially trig-
gering psychological trauma for those witness-
ing it, further research and evidence is re-
quired to guide practice and develop clear 
procedures to optimise management and at-
tain positive end-of-life outcomes. 
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